1 Patients were
randomised 1:1 to high dose (HD) IIV followed by standar
2 izumab during the upload phase and were then
randomised 1:1 to receive either the same dosage of rani
3 Patients were
randomised 1:1 to receive subcutaneous placebo or galcan
4 Patients receiving insulin were
randomised 1:1:1:1 to placebo or dapagliflozin at 2.5, 5
5 Patients were
randomised 1:2 (standard of care:dabigatran) and stratif
6 We did an open-label, non-inferiority,
randomised (
1:1 with blocks of six), multicentre, phase
7 nant women from Uganda and South Africa were
randomised (
1:1) to daily dolutegravir (50 mg) or efavir
8 sk category and type of previous therapy and
randomised (
1:1) with a complete permuted block design (
9 er randomised trial in which 75 schools were
randomised (
1:1:1) to receive the SEHER intervention del
10 In April 2015, we
randomised 80 practices to Trial 1 (40 per arm) and 64 t
11 None of the trials were
randomised and none of the individuals involved were mas
12 242 patients were
randomised and received >=1 dose of trial medication (la
13 is below 15 cm from the anal verge, will be
randomised between either a TAMIS or an ESD procedure.
14 In this
randomised,
blinded, parallel-group, pragmatic equivalen
15 In "Completely randomized" (CR) and "
Randomised block" (RB) experimental designs, both the as
16 research use "Completely randomised" (CR), "
Randomised block" (RB), or one of the more specialised n
17 SD = 8; M BMI = 34.48 kg/m2, SD = 4.87) and
randomised by a blinded researcher.
18 In the double-blind,
randomised CAPP2 trial, 861 patients from 43 internation
19 ood Assessment Chart score; <=2 vs >=3), and
randomising centre.
20 n=534), ten of whom were enrolled in the non-
randomised ChAdOx1 nCoV-19 prime-boost group.
21 th obesity (BMI >= 30 kg/m(2)) enrolled in a
randomised clinical trial (Gut Bugs Trial), to identify
22 We did an open-label,
randomised clinical trial at 57 centres in Brazil.
23 RV306 is a double-blind, placebo-controlled,
randomised clinical trial done at three clinical sites i
24 We did the first
randomised clinical trial in the USA of extracorporeal m
25 There were no
randomised clinical trials nor studies comparing outcome
26 y registered with the International Standard
Randomised Clinical Trials Number, ISRCTN79151659.
27 Despite being internationally recommended,
randomised clinical trials of ACP in patients with advan
28 ek 96 were 205 cells per muL (SD 191) in the
randomised cohort and 119 cells per muL (202) in the non
29 12 (4%) of 272 people in the
randomised cohort and 17 (17%) of 99 in the non-randomis
30 eated, of which 272 participants were in the
randomised cohort and 99 in the non-randomised cohort.
31 domised cohort and 17 (17%) of 99 in the non-
randomised cohort died; the median baseline CD4 count fo
32 fficacy of fostemsavir versus placebo in the
randomised cohort of the BRIGHTE study after 8-day funct
33 Response rates in the non-
randomised cohort were 37% (37 of 99) at week 24 and wee
34 lus optimised background therapy; or the non-
randomised cohort, in which patients with no remaining a
35 A >=400 copies per mL) into two cohorts: the
randomised cohort, in which patients with one or two ful
36 In the
randomised cohort, rates of virological suppression (HIV
37 e in the randomised cohort and 99 in the non-
randomised cohort.
38 ohort and 119 cells per muL (202) in the non-
randomised cohort.
39 m 0.20 at baseline to 0.44 at week 96 in the
randomised cohort.
40 We implemented a multi-arm, cluster-
randomised community effectiveness trial in three rural
41 echniques are standard of care, but a direct
randomised comparison is lacking.
42 included randomised control trials, cluster
randomised control trials and quasi-randomised control t
43 cluster randomised control trials and quasi-
randomised control trials comparing digital or blended e
44 We included
randomised control trials, cluster randomised control tr
45 METHODS/DESIGN: Multicenter non-inferiority
randomised controlled clinical trial.
46 frequencies are experimentally determined in
randomised controlled clinical trials.
47 The studies used a
randomised controlled experimental design, with embedded
48 A
randomised controlled non-blinded eight-arm crossover st
49 We conducted a stepped-wedge cluster-
randomised controlled trial (RCT) comparing CQI to usual
50 Better Eating and Activity Trial (UPBEAT), a
randomised controlled trial (RCT), of a lifestyle interv
51 In a future, fully powered
randomised controlled trial (RCT), retention could be im
52 In this multicentre, open-label, phase 3,
randomised controlled trial (the ENDURANCE trial; E1A11)
53 Twenty-six studies, which included one
randomised controlled trial and 25 observational studies
54 the techniques, and results from the ongoing
randomised controlled trial are need to confirm these re
55 Investigators did an open-label,
randomised controlled trial at three HIV treatment sites
56 This is the first European
randomised controlled trial comparing the effectiveness
57 ed including nonconventional alternatives to
randomised controlled trial designs.
58 R was a pragmatic, superiority, multicentre,
randomised controlled trial done at 39 hospitals in the
59 driven extension follow-up of a multicentre,
randomised controlled trial done in 85 hospitals across
60 We did a
randomised controlled trial enrolling patients with at l
61 id a multicentre, pragmatic, parallel-group,
randomised controlled trial in 12 hospitals and four pri
62 We did an open-label, non-inferiority,
randomised controlled trial in a public clinic in Durban
63 We conducted a stepped-wedge cluster-
randomised controlled trial in Eswatini to determine the
64 We did a phase 1/2, single-blind,
randomised controlled trial in five trial sites in the U
65 A
randomised controlled trial in Papua, Indonesia, compari
66 cross-sectional data collected as part of a
randomised controlled trial in private for-profit dispen
67 We report the pilot phase of a
randomised controlled trial in routine screen-and-treat
68 ered the trial on the International Standard
Randomised Controlled Trial Number (ISRCTN) (Number: 377
69 ers.TRIAL REGISTRATIONInternational Standard
Randomised Controlled Trial Number (ISRCTN) Registry, IS
70 We did an open-label, pragmatic, adaptive,
randomised controlled trial of adding oseltamivir to usu
71 community-based survey followed by a cluster
randomised controlled trial of people with hypertension
72 This double-blind, sham-controlled,
randomised controlled trial provides class I evidence of
73 This open label, parallel group,
randomised controlled trial recruited children and young
74 We conducted a cluster
randomised controlled trial to assess the effectiveness
75 SPRINT was an open-label, multicentre,
randomised controlled trial undertaken at 102 sites, inc
76 his multicentre, double-blind, parallel-arm,
randomised controlled trial was done at 13 specialist cl
77 An open-label,
randomised controlled trial was done at 19 hospitals and
78 Our two-arm, cluster-
randomised controlled trial was done in sex-work venues
79 sh (randomly selected from participants in a
randomised controlled trial), on income, food security,
80 In this 2-year cluster-
randomised controlled trial, 594 community clusters in N
81 In this open-label,
randomised controlled trial, adults (aged 16-55 years) w
82 S is registered as an International Standard
Randomised Controlled Trial, number ISRCTN22488978.
83 In this multicentre, parallel group,
randomised controlled trial, we recruited infants withou
84 ulticentre, double-blind, response-adaptive,
randomised controlled trial, we recruited patients from
85 g the use of a placebo control in a surgical
randomised controlled trial.
86 the design of a multicenter non-inferiority
randomised controlled trial.
87 dual participant data from 14 of 20 eligible
randomised controlled trials (8278 [79%] of 10 431 parti
88 Across
randomised controlled trials (k=40) and observational tr
89 ss, PsycINFO, and Science Citation Index for
randomised controlled trials (RCTs) and non-RCTs of psyc
90 ial registry platforms on July 15, 2018, for
randomised controlled trials (RCTs) and observational st
91 We systematically reviewed
randomised controlled trials (RCTs) comparing PARP inhib
92 to prospectively plan a systematic review of
randomised controlled trials (RCTs) comparing these radi
93 Several
randomised controlled trials (RCTs) have assessed if ind
94 However,
randomised controlled trials (RCTs) investigating the im
95 are increasingly considered for inclusion in
randomised controlled trials (RCTs) involving patients w
96 spects, are increasingly evaluated in cancer
randomised controlled trials (RCTs) to provide informati
97 observational prospective studies (OPSs) and
randomised controlled trials (RCTs) were included.
98 We enrolled double-blind,
randomised controlled trials (RCTs).
99 were included in the analysis, including 30
randomised controlled trials and 12 cohort studies.
100 Randomised controlled trials are considered the gold sta
101 Double-blind
randomised controlled trials comparing clozapine with ot
102 EDLINE, Embase, and The Cochrane Library for
randomised controlled trials comparing parenteral antico
103 individual participant data meta-analysis of
randomised controlled trials examines the effect of hepa
104 non-pregnant adults, few published data from
randomised controlled trials have compared the safety an
105 Four
randomised controlled trials have tested the efficacy of
106 terventions for Pre-eclampsia (CLIP) cluster
randomised controlled trials in Mozambique, Pakistan, an
107 stenosis is consistent with the two previous
randomised controlled trials in younger cohorts, support
108 We included
randomised controlled trials of cardiovascular outcomes
109 nstruction should ideally be investigated by
randomised controlled trials of pragmatic design.
110 Use of placebo controls is justified in
randomised controlled trials of surgical interventions p
111 we used data from three previously reported
randomised controlled trials to estimate lifetime gains
112 These findings highlight the need to do
randomised controlled trials to test higher transfusion
113 d immunotherapy which should be evaluated in
randomised controlled trials.
114 to optimise the design and implementation of
randomised controlled trials.
115 vational cohort and case-control studies and
randomised controlled trials.
116 We did a cluster-
randomised controlled, open-label trial using a two-by-t
117 This multicentre,
randomised,
controlled cross-over trial was designed to
118 AN is an ongoing, open-label, sponsor-blind,
randomised,
controlled phase 3 trial at 209 cancer treat
119 We did a
randomised,
controlled trial involving 23 breast screeni
120 This phase 2, open-label, multicentre,
randomised,
controlled trial was undertaken at six clini
121 sis includes data from four ongoing blinded,
randomised,
controlled trials done across the UK, Brazil
122 This
randomised,
controlled, double-blind, multicentre, non-i
123 of the phase 2 component of a single-blind,
randomised,
controlled, phase 2/3 trial (COV002), health
124 DANUBE is an open-label,
randomised,
controlled, phase 3 trial in patients with u
125 This multicentre, double-blind,
randomised,
controlled, phase 3 trial was done in 130 ac
126 In this open-label,
randomised,
controlled, phase 3, three-arm, Gynecologic
127 ucted a hybrid implementation-effectiveness,
randomised,
controlled, unblinded, parallel-group pilot
128 e empirical networks as well as that of some
randomised counterparts, and examine the extent to which
129 ged in pre-clinical research use "Completely
randomised" (
CR), "Randomised block" (RB), or one of the
130 nd extended feeding (EXF, 15 h day(-1)) in a
randomised cross-over design (trial registration: ACTRN1
131 idem or placebo according to a double-blind,
randomised,
cross-over design.
132 ross two sessions in a double-blinded pseudo-
randomised crossover design.
133 Utilising a double-blind,
randomised crossover study design, we recruited 20 healt
134 ributed between patient groups given the non-
randomised design of the studies included.
135 Randomised designs and controlled observational designs
136 sing fMRI task at least 8 days apart using a
randomised double-blind crossover design.
137 A
randomised double-blinded trial of 3 pyrethroid LLIN pro
138 REWIND is a
randomised,
double-blind placebo-controlled trial at 371
139 This study is an ongoing,
randomised,
double-blind, multicentre, active-controlled
140 This
randomised,
double-blind, parallel-group, multicentre pl
141 SPI2 was a
randomised,
double-blind, parallel-group, placebo-contro
142 RESTORE BRAIN was an international,
randomised,
double-blind, parallel-group, placebo-contro
143 We did a multicentre,
randomised,
double-blind, phase 2 study for adult patien
144 This
randomised,
double-blind, phase 3, placebo-controlled, m
145 We did this
randomised,
double-blind, placebo-controlled phase 1 tri
146 IMspire150 was a
randomised,
double-blind, placebo-controlled phase 3 stu
147 We performed a multicentre,
randomised,
double-blind, placebo-controlled randomised
148 The MS-SPI
randomised,
double-blind, placebo-controlled study found
149 This
randomised,
double-blind, placebo-controlled study was d
150 patients with irritable bowel syndrome in a
randomised,
double-blind, placebo-controlled study.
151 We did a multicentre, phase 2/3,
randomised,
double-blind, placebo-controlled trial at 92
152 This was a
randomised,
double-blind, placebo-controlled trial of vi
153 estinal bleeding (HALT-IT): an international
randomised,
double-blind, placebo-controlled trial.
154 IBIS-II is an international,
randomised,
double-blind, placebo-controlled trial.
155 BE ACTIVE was a
randomised,
double-blind, placebo-controlled, dose-rangi
156 We did a
randomised,
double-blind, placebo-controlled, event-driv
157 We did a
randomised,
double-blind, placebo-controlled, phase 2 tr
158 This multicentre,
randomised,
double-blind, placebo-controlled, phase 3 st
159 COMBI-AD is a
randomised,
double-blind, placebo-controlled, phase 3 tr
160 BROCADE3 was a
randomised,
double-blind, placebo-controlled, phase 3 tr
161 We did a
randomised,
double-blind, placebo-controlled, trial at 3
162 Participants were
randomised equally to either receive oral rosuvastatin (
163 the form of the Applying Surgical Placebo in
Randomised Evaluations (known as ASPIRE) checklist, for
164 tween 1790 and 2012 were grown in replicated
randomised field trials for three years, milled, and whi
165 was no difference in adverse events between
randomised groups.
166 1,503 (93.4%); follow-up was similar between
randomised groups.
167 The BCPP was a community-
randomised HIV-prevention trial done in 30 communities a
168 al-time, dynamic, internet-based, stratified
randomised minimisation procedure.
169 In this
randomised,
multicentre, open-label, phase 3 study, 466
170 ASPIRIN was a
randomised,
multicountry, double-masked, placebo-control
171 This was a prospective, non-
randomised,
non-blinded, consecutive cohort study conduc
172 n stenosis: updated 5-year outcomes from the
randomised,
non-inferiority NOBLE trial.
173 FAST-Forward is a multicentre, phase 3,
randomised,
non-inferiority trial done at 97 hospitals (
174 We did an open-label,
randomised,
non-inferiority, phase 3 trial in 31 transpl
175 bstudies within the open-label, multicentre,
randomised ODYSSEY trial (NCT02259127) of children with
176 We did a
randomised,
open-label trial in eight academic hospitals
177 This phase 3,
randomised,
open-label trial was done at 123 sites in 21
178 In this
randomised,
open-label trial, DolPHIN-2, we recruited pr
179 We did a multicentre,
randomised,
open-label trial, with blinded outcome asses
180 CASSIOPEIA is an ongoing
randomised,
open-label, active-controlled, parallel-grou
181 ALCYONE was a multicentre,
randomised,
open-label, active-controlled, phase 3 trial
182 We did a prospective,
randomised,
open-label, blinded-endpoint, non-inferiorit
183 FeDeriCa, a
randomised,
open-label, international, multicentre, non-
184 This was a
randomised,
open-label, multicentre, phase 3 trial done
185 The prospective,
randomised,
open-label, non-inferiority NOBLE trial was
186 This
randomised,
open-label, non-inferiority phase 3 trial, w
187 Oncology Group and NRG Oncology multicentre,
randomised,
open-label, phase 2 trial, we enrolled eligi
188 In the ongoing,
randomised,
open-label, phase 3 KEYNOTE-426 study, adult
189 We report the 5-year results for a
randomised,
open-label, phase 3 study (RESPONSE) that en
190 CLL14 is a multicentre,
randomised,
open-label, phase 3 trial done at 196 sites
191 The LACC trial was a
randomised,
open-label, phase 3, non-inferiority trial d
192 PubMed and Embase between 1970 and 2019 for
randomised or otherwise controlled studies and observati
193 grees C and core heating by 1.5 degrees C in
randomised order at sea level; acute hypoxia ( PET,O2 =
194 Randomised order of clinician and self-samples from phar
195 Randomised order of clinician and self-samples from phar
196 In an exploratory, block-
randomised,
parallel, double-blind, single-centre, place
197 Sixty-three participants for this
randomised,
parallel-group, double-blind, placebo-contro
198 This
randomised,
parallel-group, placebo-controlled, double-b
199 in the full analysis set, which included all
randomised patients who received at least one dose of st
200 Of the
randomised patients, 107 each were treated with fingolim
201 intention-to-treat population comprised all
randomised patients, regardless of treatment administrat
202 escriptively across treatment groups for all
randomised patients.
203 Six non-
randomised phase 1/2A cell therapy group (CTG) trials we
204 the triplet therapy, are being compared in a
randomised phase 2 trial (NCT01896999).
205 In this open-label, investigator-initiated,
randomised phase 2 trial following a selection (or pick-
206 A
randomised phase 3 clinical trial assessing the efficacy
207 In this multicentre, double-blind,
randomised phase 3 trial (JADE MONO-1), patients (aged >
208 with doxorubicin as second-line therapy in a
randomised phase 3 trial.
209 A prospective, pooled analysis of six
randomised phase 3 trials was done to investigate diseas
210 In the absence of
randomised phase 3 trials, early clinical studies show i
211 In this prospective, pooled analysis of six
randomised phase 3 trials, we included patients with sta
212 In this multicentre, open-label,
randomised,
phase 2 study, 11 different centres in the U
213 We did an open-label, multicentre,
randomised,
phase 2 trial at six hospitals in China.
214 ICON8 was an international, multicentre,
randomised,
phase 3 trial done across 117 hospitals in t
215 This multicentre, open-label,
randomised,
phase 3 trial, was done in 159 academic cent
216 18 countries), open-label, non-inferiority,
randomised,
phase 3 trial, we recruited adult patients (
217 s therapeutic approach has been validated in
randomised,
phase 3 trials, evaluation of response to ne
218 2b, multiarm, parallel group, double-blind,
randomised placebo-controlled trial at 13 clinical neuro
219 clinical significance, there is a paucity of
randomised,
placebo-controlled clinical trial evidence w
220 HPTN 077 was a multicentre, double-blind,
randomised,
placebo-controlled phase 2a trial done at ei
221 atic arthritis (DISCOVER-2): a double-blind,
randomised,
placebo-controlled phase 3 trial.
222 For this multicentre, double-blind,
randomised,
placebo-controlled study done in 48 acute ca
223 A 24-week, double-blinded,
randomised,
placebo-controlled trial (ClinicalTrials.gov
224 We did a multicentre, double-blind,
randomised,
placebo-controlled, dose-response study at 1
225 In this
randomised,
placebo-controlled, double-blind, phase 1 tr
226 In this
randomised,
placebo-controlled, double-blind, phase 3 tr
227 In this
randomised,
placebo-controlled, double-blind, phase 3 tr
228 In this
randomised,
placebo-controlled, four-sequence, four-peri
229 In this international, double-blind,
randomised,
placebo-controlled, phase 3 study (D-CARE),
230 In this double-blind,
randomised,
placebo-controlled, phase 3 study, we enroll
231 an international, multicentre, double-blind,
randomised,
placebo-controlled, phase 3 trial done at 18
232 This was a double-blind,
randomised,
placebo-controlled, phase 3 trial that was d
233 In this ongoing (enrolment complete)
randomised,
placebo-controlled, phase 3 trial, patients
234 The phase 2,
randomised portion of the trial is still enrolling.
235 Further research in a
randomised setting is needed to determine predictors of
236 MATERIALS/METHODS: A
randomised single-blind controlled trial of IIV in autoH
237 s an investigator-initiated, open-label, non-
randomised,
single-arm, single centre, phase 2 trial in
238 Future larger and
randomised studies are needed to clarify activity in hig
239 t recommendations and controlled, preferably
randomised studies are warranted in order to formulate e
240 We did two
randomised studies at two centres in Belgium.
241 Fourth, use of non-
randomised studies for the evaluation of clinical benefi
242 To our knowledge, this is the first
randomised study of an ATR inhibitor in any tumour type.
243 n a multicentre, parallel-group, open-label,
randomised study, children (aged 0-17 years) attending 1
244 opensity score matching resulted in a pseudo-
randomised sub-cohort balancing baseline demographic and
245 lel-group, multicentre, open-label, two-arm,
randomised superiority trial included adults (aged 16 ye
246 al is ongoing, with 55 patients remaining on
randomised therapy as of Feb 20, 2020.
247 Randomised therapy was discontinued in 973 (32.4%) patie
248 Eligible children were
randomised to dolutegravir in ODYSSEY and weighed 20 kg
249 ealthy University of Cambridge students were
randomised to join an 8-week mindfulness course (N = 27)
250 iple sclerosis (MS) (aged 10-<18 years) were
randomised to once-daily oral fingolimod (n=107) or once
251 ea Scoring Index (F-VASI) at week 24 were re-
randomised to one of three higher ruxolitinib cream dose
252 pant participants and 5 (3%) of 186 of those
randomised to placebo.
253 ons, all mild, reported by five participants
randomised to rosuvastatin, and one serious adverse even
254 thout detected resistance and those who were
randomised to standard of care received NNRTI-based firs
255 Efficacy analyses were done in all patients
randomised to three nested cohorts: patients with BRCA m
256 ed to three categories "Design acceptable", "
Randomised to treatment groups", so of doubtful validity
257 Outcomes of GDM-affected pregnancies
randomised to treatment with metformin, glyburide, or in
258 as first introduced in 2006 during a cluster
randomised trial conducted before nationwide introductio
259 Randomised trial data assessing the safety and efficacy
260 AFFIRM-AHF was a multicentre, double-blind,
randomised trial done at 121 sites in Europe, South Amer
261 ARUBA was a non-blinded,
randomised trial done at 39 clinical centres in nine cou
262 ion Project study was a pair-matched cluster-
randomised trial done in 30 communities across Botswana
263 Multicenter
randomised trial in 15 hospitals in the Netherlands.
264 with advanced cancer, we conducted a cluster-
randomised trial in 23 hospitals across Belgium, Denmark
265 ic, outcome-assessor-blinded, parallel-group
randomised trial in 3 Australian hospitals in Sydney and
266 randomised, double-blind, placebo-controlled
randomised trial in 39 UK hospital centres.
267 evaluated using data from a large, household-
randomised trial in Hounde, Burkina Faso and Bougouni, M
268 In this cluster-
randomised trial in Kumasi, Ghana and Ibadan, Nigeria, w
269 DEEP-2 was a phase 3, multicentre,
randomised trial in paediatric patients (aged 1 month to
270 We did a cluster
randomised trial in rural refugee settlements in norther
271 We conducted a cluster
randomised trial in which 75 schools were randomised (1:
272 We embedded a pragmatic cluster-
randomised trial into Uganda's national LLIN campaign to
273 A prospective
randomised trial is needed to evaluate whether a second
274 efits or risks in settings, in which doing a
randomised trial is not feasible.
275 icipants with Lynch syndrome enrolled into a
randomised trial of daily aspirin versus placebo.
276 RIVER is the first
randomised trial to determine the effect of ART-only ver
277 lticentre, pragmatic, three-arm, superiority
randomised trial, patients referred to secondary care fo
278 single-centre, double-blind, parallel-group,
randomised trial, patients with advanced cancer, aged at
279 In this multicentre, phase 3,
randomised trial, untreated patients aged 18 years or ol
280 In this cluster-
randomised trial, we included 30 health centres offering
281 In a double-blind, parallel-group
randomised trial, we recruited adult participants identi
282 In this cluster-
randomised trial, we recruited participants aged 15 year
283 In this multicentre, open-label,
randomised trial, we recruited patients with uncomplicat
284 udy met criteria to move forward to a future
randomised trial.
285 risons are increasingly being considered for
randomised trials assessing the efficacy of surgical int
286 aluating a product's net clinical benefit in
randomised trials compared with current known effective
287 Community
randomised trials have had mixed success in implementing
288 Previous
randomised trials have shown an overwhelming benefit of
289 wo single-centre, multi-site, partly-masked,
randomised trials in healthy cohorts of children (aged 1
290 Randomised trials of intravenous alteplase versus standa
291 Fifth, efficiency of
randomised trials should be improved by streamlining pat
292 Whilst
randomised trials show that children exposed to less-hea
293 We undertook two parallel, pragmatic cluster-
randomised trials using balanced incomplete block design
294 k meta-analyses based on existing and future
randomised trials.
295 KD, but this requires testing in prospective
randomised trials.
296 Ten participants assigned to a non-
randomised,
unblinded ChAdOx1 nCoV-19 prime-boost group
297 We did a household-
randomised,
unblinded trial (DO ART) of delivery of ART
298 servation period, eligible participants were
randomised using an interactive web response system to o
299 5, and April 11, 2017, 197 kidney pairs were
randomised with 106 pairs transplanted into eligible rec
300 Twenty-two studies (n = 2,801)
randomised women to metformin versus insulin, 8 studies